APXZF (Carasent AB (publ)) Altman Z-Score: 6.70 (As of Jun. 29, 2026) — Near Median


APXZF Carasent AB (publ) APXZF
80 GF Score
Price $0.15
GF Value $0.18
! 3 Warning Signs
View Full Analysis

What is Carasent AB (publ) Altman Z-Score?

Carasent AB (publ) APXZF 80 Altman Z-Score is 6.70 as of Jun. 29, 2026, which is 3% below its 10-year median of 6.91. GuruFocus rates APXZF with a GF Score™ of 80/100 and a GF Value™ of $0.18. The stock has 3 warning signs investors should review. Among 657 Healthcare Providers & Services companies, Carasent AB (publ) ranks better than 83.87% on this metric.

The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.

Good Sign:

Altman Z-score of 6.99 is strong.

Carasent AB (publ) has a Altman Z-Score of 6.70, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.

The zones of discrimination were as such:

When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.

The historical rank and industry rank for Carasent AB (publ)'s Altman Z-Score or its related term are showing as below:

APXZF' s Altman Z-Score Range Over the Past 10 Years
Min: 1.08   Med: 6.91   Max: 136.08
Current: 6.99

During the past 13 years, Carasent AB (publ)'s highest Altman Z-Score was 136.08. The lowest was 1.08. And the median was 6.91.


Carasent AB (publ)  (OTCPK:APXZF) Altman Z-Score Explanation

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.

X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.

Read more about Altman Z-Score and the original research.


Be Aware

Altman Z-Score does not apply to financial companies.


Carasent AB (publ) Altman Z-Score Related Terms


Carasent AB (publ) Altman Z-Score Historical Data

* Premium members only.

The historical data trend for Carasent AB (publ)'s Altman Z-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Carasent AB (publ) Altman Z-Score Chart

Carasent AB (publ) Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Altman Z-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.48 5.98 3.85 5.60 9.00

Carasent AB (publ) Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Altman Z-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.56 7.64 7.27 9.00 7.01

APXZF vs VEEV, BTSG, TEM: Altman Z-Score Comparison

For the Health Information Services subindustry, Carasent AB (publ)'s Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Carasent AB (publ) Altman Z-Score vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Carasent AB (publ)'s Altman Z-Score distribution charts can be found below:

* The bar in red indicates where Carasent AB (publ)'s Altman Z-Score falls into.


APXZF
80GF Score
Carasent AB (publ) APXZF
Altman Z-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Carasent AB (publ) Altman Z-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Carasent AB (publ)'s Altman Z-Score for today is calculated with this formula:

Z=1.2*X1+1.4*X2+3.3*X3+0.6*X4+1.0*X5
=1.2*0.0777+1.4*-0.062+3.3*0.0402+0.6*10.3161+1.0*0.3762
=6.70

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.

Trailing Twelve Months (TTM) ended in Mar. 2026:
Total Assets was $98.94 Mil.
Total Current Assets was $20.99 Mil.
Total Current Liabilities was $13.30 Mil.
Retained Earnings was $-6.13 Mil.
Pre-Tax Income was 0.321 + 3.181 + 0.871 + -0.401 = $3.97 Mil.
Interest Expense was 0 + 0 + 0 + -0.01 = $-0.01 Mil.
Revenue was 9.703 + 10.068 + 8.77 + 8.679 = $37.22 Mil.
Market Cap (Today) was $157.05 Mil.
Total Liabilities was $15.22 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(20.988 - 13.303)/98.944
=0.0777

X2=Retained Earnings/Total Assets
=-6.133/98.944
=-0.062

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(3.972 - -0.01)/98.944
=0.0402

X4=Market Value Equity/Book Value of Total Liabilities
=Market Cap/Total Liabilities
=157.052/15.224
=10.3161

X5=Revenue/Total Assets
=37.22/98.944
=0.3762

The zones of discrimination were as such:

Distress Zones - 1.81 < Grey Zones < 2.99 - Safe Zones

Carasent AB (publ) has a Altman Z-Score of 6.70 indicating it is in Safe Zones.

Study by Altman found that companies that are in Distress Zone have more than 80% of chances of bankruptcy in two years.

Frequently Asked Questions Learn more about Altman Z-Score →
What does a Altman Z-Score of 6.70 mean?
Carasent AB (publ) (APXZF) has a Altman Z-Score of 6.70 as of Jun. 29, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Carasent AB (publ) and its competitors. This is near median its historical median of 6.91. Over the past decade, Carasent AB (publ)'s Altman Z-Score has ranged from 1.08 to 136.08. According to the industry distribution chart, Carasent AB (publ) ranks #106 out of 657 companies in the Healthcare Providers & Services industry, placing it in the top 16.1%.
Is Carasent AB (publ)'s Altman Z-Score too high?
Carasent AB (publ)'s current Altman Z-Score of 6.70 is near median its 10-year median of 6.91. Over the past 10 years, this metric has ranged from a low of 1.08 to a high of 136.08. The Healthcare Providers & Services industry median Altman Z-Score is 2.38. Carasent AB (publ)'s value of 6.70 is 181.5% above this industry median. Based on the distribution chart, Carasent AB (publ) ranks #106 out of 657 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Carasent AB (publ) has a GF Score™ of 80/100, reflecting its overall financial health beyond just this single metric.
How does Carasent AB (publ)'s Altman Z-Score compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Carasent AB (publ) ranks #106 out of 657 companies for Altman Z-Score. This places Carasent AB (publ) in the top 16% of its industry — outperforming the majority of peers. The industry median Altman Z-Score is 2.38. Carasent AB (publ)'s value of 6.70 is 181.5% above this benchmark. Historically, Carasent AB (publ)'s own Altman Z-Score has ranged from 1.08 to 136.08 over the past decade. While the company's 10-year median is 6.91 vs. the industry median of 2.38, Carasent AB (publ) has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Healthcare Providers & Services company?
The median Altman Z-Score among Healthcare Providers & Services companies is 2.38, based on 657 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Carasent AB (publ)'s current Altman Z-Score of 6.70 is 181.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Carasent AB (publ) and its competitors. For the Healthcare Providers & Services industry, the median Altman Z-Score is 2.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Carasent AB (publ)'s current Altman Z-Score is 6.70, which is near median its own 10-year median of 6.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carasent AB (publ) stock overvalued right now?
Carasent AB (publ) (APXZF) has a current Altman Z-Score of 6.70. The stock's GF Value™ is $0.18, compared to a current price of $0.15 — trading 16.7% below its estimated fair value. The current Altman Z-Score is 6.70, which is near median its 10-year median of 6.91 and 181.5% above the Healthcare Providers & Services industry median of 2.38. Carasent AB (publ)'s overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Carasent AB (publ) (APXZF), the current Altman Z-Score is 6.70 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Carasent AB (publ) (APXZF) Overvalued in 2026?

Based on GuruFocus' analysis, Carasent AB (publ) stock appears to be undervalued. The current stock price of $0.15 is trading 16.7% below its estimated GF Value™ of $0.18.

Key valuation signals for APXZF:

  • Altman Z-Score: 6.70 (near median its 10-year median of 6.91)
  • GF Value™: $0.18 vs. price of $0.15 (16.7% below fair value)
  • GF Score™: 80/100 with 3 warning signs
  • Industry Position: 181.5% above the Healthcare Providers & Services median (#106 of 657)

No single metric tells the full story. See the APXZF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Carasent AB (publ) Business Description

Other Exchanges CARA:SwedenE0C:Germany
Address Nellickevagen 24C, Gothenburg, NOR, 412 63
Carasent AB (publ) Formerly Carasent AB is a comprehensive provider of cloudbased EHR solutions and platform services for various organizations within the healthcare sector. With Webdoc as the main product, the group offers a broad ecosystem of services, including solutions for patient communication and business intelligence. Geographically, the company operates in the Nordic region and Germany. It derives maximum revenue from Nordic Region. The solutions provides by the group are: Webdoc; Metodika; Medrave; HPI plustoo; Ad Curis; Ad Opus; Webcur; Data-AL; and Data-Cur.
80GF Score

Get the complete analysis for APXZF

Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.15
Price
$0.18
GF Value